Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CAMP

CAMP4 Therapeutics (CAMP) Stock Price, News & Analysis

CAMP4 Therapeutics logo

About CAMP4 Therapeutics Stock (NASDAQ:CAMP)

Advanced Chart

Key Stats

Today's Range
$3.52
$4.67
50-Day Range
$0.40
$4.00
52-Week Range
$1.31
$12.30
Volume
58,479 shs
Average Volume
2.16 million shs
Market Capitalization
$65.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.50
Consensus Rating
Buy

Company Overview

CAMP4 Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

CAMP MarketRank™: 

CAMP4 Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 297th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CAMP4 Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Upside Potential

    CAMP4 Therapeutics has a consensus price target of $16.50, representing about 408.3% upside from its current price of $3.25.

  • Amount of Analyst Coverage

    CAMP4 Therapeutics has received no research coverage in the past 90 days.

  • Read more about CAMP4 Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for CAMP4 Therapeutics are expected to grow in the coming year, from ($4.99) to ($2.89) per share.

  • Price to Book Value per Share Ratio

    CAMP4 Therapeutics has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    8.28% of the float of CAMP4 Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CAMP4 Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • Dividend Yield

    CAMP4 Therapeutics does not currently pay a dividend.

  • Dividend Growth

    CAMP4 Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.28% of the float of CAMP4 Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CAMP4 Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • News Coverage This Week

    MarketBeat has tracked 14 news articles for CAMP4 Therapeutics this week, compared to 0 articles on an average week.
  • Search Interest

    6 people have searched for CAMP on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CAMP4 Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,054,994.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    33.60% of the stock of CAMP4 Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about CAMP4 Therapeutics' insider trading history.
Receive CAMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CAMP4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CAMP Stock News Headlines

Nashat Amir buys Camp4 Therapeutics (CAMP) shares worth $1.99m
Major Investments Pour into CAMP4 Therapeutics Corporation!
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social Security? What we just discovered in Washington will stun even the most seasoned insiders.tc pixel
CAMP4 Therapeutics stock soars after $100 million private placement
CAMP4 Therapeutics Secures $100M in Private Placement
See More Headlines

CAMP Stock Analysis - Frequently Asked Questions

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) released its quarterly earnings results on Thursday, August, 14th. The Wireless communications provider reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.05. The Wireless communications provider had revenue of $1.50 million for the quarter, compared to the consensus estimate of $0.73 million.

CAMP4 Therapeutics's stock reverse split before market open on Friday, February 2nd 2024.The 1-23 reverse split was announced on Friday, February 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

The following companies are subsidiaries of CAMP4 Therapeutics: LoJack, Gulfstream Telematics, SmartLink Radio Networks, CalAmp Wireless Networks Inc., Skybility, Boisen S.A., CalAmp Importation and Leasing of Tracking Equipment Ltd., and more.

CAMP4 Therapeutics (CAMP) raised $75 million in an IPO on Friday, October 11th 2024. The company issued 6,820,000 shares at a price of $11.00 per share.

Top institutional investors of CAMP4 Therapeutics include Geode Capital Management LLC (0.37%) and Bridgeway Capital Management LLC (0.12%). Insiders that own company stock include Polaris Management Co Vii, L, Amir Nashat, Josh Mandel-Brehm, Richard A Young, Kelly Gold, Jeffery R Gardner, Yuri Maricich and Jason Cohenour.
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that CAMP4 Therapeutics investors own include Zimmer Biomet (ZBH), Union Pacific (UNP), Charter Communications (CHTR), NVIDIA (NVDA), PayPal (PYPL), MercadoLibre (MELI) and Meta Platforms (META).

Company Calendar

Last Earnings
8/14/2025
Today
9/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Communications Equipment
Current Symbol
NASDAQ:CAMP
CIK
730255
Employees
644
Year Founded
1981

Price Target and Rating

High Price Target
$23.00
Low Price Target
$8.00
Potential Upside/Downside
+408.3%
Consensus Rating
Buy
Rating Score (0-4)
3.17
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$51.79 million
Net Margins
N/A
Pretax Margin
-1,722.08%
Return on Equity
N/A
Return on Assets
-96.92%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.60
Quick Ratio
5.60

Sales & Book Value

Annual Sales
$650 thousand
Price / Sales
100.68
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.13 per share
Price / Book
1.04

Miscellaneous

Outstanding Shares
20,160,000
Free Float
13,387,000
Market Cap
$65.44 million
Optionable
No Data
Beta
N/A

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:CAMP) was last updated on 9/12/2025 by MarketBeat.com Staff
From Our Partners